Literature DB >> 1001220

Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications.

E Hempel, W Klinger.   

Abstract

On the basis of well documented biochemical and pharmacological data about the influence of drug mediated enzyme induction on the biotransformation of natural and synthetic sex steroids, practical consequences for hormonal steroid contraception are described and discussed. Clinical reports dealing with this problem are still sparse. The clinical symptoms of drug stimulated biotransformation of hormonal steroid contraceptives are characteristic. Spotting or breakthrough bleeding are observed and in the extreme case conception may occur despite the regular intake of the contraceptive. The appearance of these symptoms differs from one individual to another. With a strong enzyme inducer, bleeding disorders can be provoked artifically in 50 to 60% of the women receiving hormonal contraceptive treatment. The range of drugs which stimulate biotransformation of hormonal contraceptives with consequent loss of their biological effectiveness is not completely known. For practical purposes, it is recommended that bleeding disturbances under hormonal steroid contraception in a previously regular cycle be regarded as loss of reliability; they should be remedied and taken as a sign to search for uncontrolled drug taking.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1001220     DOI: 10.2165/00003495-197612060-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  15 in total

1.  The interaction of steroids with liver microsomal cytochrome P-450--a general hypothesis.

Authors:  R W Estabrook; G Martinez-Zedillo; S Young; J A Peterson; J McCarthy
Journal:  J Steroid Biochem       Date:  1975 Mar-Apr       Impact factor: 4.292

Review 2.  Pharmacokinetic drug interactions. Sedative, hypnotic, and antianxiety agents.

Authors:  M E Kosman
Journal:  JAMA       Date:  1974-09-09       Impact factor: 56.272

3.  [Effects of rifampicin on the menstrual cycle and on oestrogen excretion in patients taking oral contraceptives].

Authors:  L Nocke-Finck; H Breuer; D Reimers
Journal:  Dtsch Med Wochenschr       Date:  1973-08-11       Impact factor: 0.628

4.  [Rifampicin and oral contraceptives (author's transl)].

Authors:  R Kropp
Journal:  Prax Pneumol       Date:  1974-05

5.  In vitro inhibition of drug metabolism by metabolites of progesterone.

Authors:  L F Soyka; R J Long
Journal:  J Pharmacol Exp Ther       Date:  1972-08       Impact factor: 4.030

6.  [Increased hydroxylation of estrogens in humans after administration of drugs. Demonstration by HTO analysis of body water].

Authors:  M Wenzel; H J Stahl
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1970-06

7.  [A simple in vivo test for barbiturate induced hydroxylases using tritium labelled steroids as indicators].

Authors:  M Wenzel; G Köster; J Hönicke
Journal:  Z Klin Chem Klin Biochem       Date:  1970-05

8.  [The effect of estrogens on oxidative biotransformation reactions in the rat liver].

Authors:  W Klinger; A Neugebauer; F K Splinter; K H Chemnitius
Journal:  Biochem Pharmacol       Date:  1970-10       Impact factor: 5.858

9.  Glucaric acid as an indicator of use of enzyme-inducing drugs.

Authors:  E A Sotaniemi; F Medzihradsky; G Eliasson
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

Review 10.  [Influence of drugs on steroid hormone biotransformation].

Authors:  W Klinger
Journal:  Z Arztl Fortbild (Jena)       Date:  1971-12-15
View more
  12 in total

1.  [Ultrastructural-morphometric investigations on liver biopsies--the influence of oral contraceptives on the human liver (author's transl)].

Authors:  K Stahl; H Themann; A Verhagen
Journal:  Arch Gynakol       Date:  1977-10-28

Review 2.  Treatment of concomitant illnesses in patients receiving anticonvulsants: drug interactions of clinical significance.

Authors:  P Loiseau
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

3.  Interaction between oral contraceptives and griseofulvin.

Authors:  C P van Dijke; J C Weber
Journal:  Br Med J (Clin Res Ed)       Date:  1984-04-14

Review 4.  Drug interactions with phenytoin.

Authors:  E Perucca; A Richens
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

Review 5.  Interactions with antiepileptic drugs.

Authors:  A Richens
Journal:  Drugs       Date:  1977-04       Impact factor: 9.546

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

9.  Pharmacokinetic interactions with rifampicin.

Authors:  W Zilly; D D Breimer; E Richter
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

10.  Drug withdrawal and epilepsy. When and how?

Authors:  D Chadwick
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.